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Abstract
Kaposi sarcoma-associated herpesvirus (KSHV) is the etiological agent of several human
malignancies. The virus is able to modulate pro-proliferative pathways to its advantage, while
simultaneously inhibiting pro-apoptotic signaling pathways. These functions are carried out by
multiple viral proteins acting in concert. The overall outcome is the survival and proliferation of
the infected cell. Additionally, the virus also modulates innate immune pathways to allow for
prolonged survival of the infected cell following primary infection, and during viral latency. Here
we review the latest advances in our knowledge of KSHV pathogenesis.
Introduction
Infection with Kaposi sarcoma-associated herpesvirus (KSHV) drives viral pathogenesis.
The clinical and molecular phenotypes of these infection events are diverse and depend on
the cellular environment (B cell lineage or endothelial cell lineage) as well as host cell
mutations that are acquired during progressive transformation steps. KSHV pathogenesis
also depends on cell extrinsic events such as co-infection with human immunodeficiency
virus (HIV), degree and status of the systemic host immune response, and other host factors,
which modulate the cellular environment. Currently, there is no molecular evidence that
KSHV pathogenesis differs among distinct KSHV strains or clades, though SNPs in both
miRNA and gene coding regions have been identified and associated with altered gene
expression [1,2].
During much of its life cycle, the KSHV virus is present in a latent form. Here, only a very
limited set of viral genes is expressed. They ensure maintenance and faithful segregation of
the viral genome during host cell division and they ensure continued cell survival (reviewed
in [3]). KSHV is able to increase the life span of infected cells and primary infection induces
some features e.g. activation of pro-survival signaling pathways, that are commonly seen in
transformed cells [4-6]. Individual viral genes and microRNAs augment proliferation in
multiple experimental systems and also modulate autophagy and oncogene-induced
senescence [3,7-9]. To ensure continued cell survival, KSHV infection also modulates
cellular immunity. Recent evidence also indicates that KSHV modulates various metabolic
pathways in B cells and endothelial cells to its advantage [10-12].
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KSHV in endothelial cells
KSHV infects endothelial lineage cells. Clinically, KSHV infected endothelial cells
constitute the bulk of Kaposi sarcoma (KS) lesions. KS lesions are composed of elongated,
spindle-like, endothelial cells. All endothelial cells within a KS tumor are infected with the
virus and express the KSHV latent genes, including all viral miRNAs [13,14]. Clinically,
there is little evidence for long-term KSHV infected endothelial cells outside of KS lesions,
or prior to KS disease manifestation. In infected endothelial lineage culture systems, KSHV
is rapidly lost unless the latently infected cells undergo additional transforming events
[5,6,15-17], or the virus is selected for [18]. This suggests that infection of endothelial
lineage cells with KSHV places severe selection on the host cell, leading either to viral
replication, viral clearance, or persistence in a transformed cell.
The many manifestations of Kaposi Sarcoma
KS (Figure 1) manifests itself in multiple forms: (i) classic KS, which is a rare disease of the
elderly, (ii) endemic KS, which is a frequent disease of children in sub-Saharan Africa and
was documented before the introduction of HIV, (iii) AIDS-associated KS, which marks the
terminal stages of HIV infection, and (iv) iatrogenic KS, which develops in solid organ
transplant recipients (reviewed in [3]). Endemic, HIV-negative KS is seen both in children
and in adults with elevated incidence. In the absence of reliable pathology and a reliable
clinical reporting structure, it is unclear whether the KS in these two age groups represent
different diseases, whether there is a genetic predisposition that is associated with pediatric
KS, or whether there exists age and environment specific environmental factors. KS
incidence is also elevated in isolated parts of China [19]. AIDS-associated KS presents in
multiple clinical situations as well, which may represent multiple variations in KSHV
pathogenesis. Prior to the introduction of combination antiretroviral therapy (cART), AIDS
KS was negatively correlated with CD4 counts. The majority of AIDS KS continues to
present in persons with low CD4 counts and indicates cART failure. However, 1/3 of KS
now presents in HIV+ individuals on successful long-term cART, despite undetectable HIV
viral load and despite near-normal CD4 counts [20]. Lastly, KS immune reconstitution
syndrome has been recognized as a complication of cART initiation, where rapid immune
restoration leads to the development of KS lesions [21]. Based on limited data, KS that
develops in HIV-suppressed individuals exhibits a more restricted viral gene expression
profile [13].
The molecular drivers of KS are unclear. On the one hand, we do not know of any specific
mutation that is associated with KS. On the other hand, we do know the transcriptional
profiles of KS and endothelial-based model systems for KS. Profiling studies, together with
the analyses of individual proteins, confirm that the tissue of origin for KS is an endothelial
cell. More detailed lineage assignments are difficult to make. There exists evidence of trans-
or de-differentiation of endothelial cells in response to KSHV infection and/or
transformation to KS tumor cells as well as evidence for the expression of markers not
exclusively associated with endothelial cells [15,22]. The most exciting recent discovery is
that of the ephA2 receptor kinase as a receptor for KSHV [23,24].
KSHV-Inflammatory Cytokine Syndrome (KICS)
Primary KSHV infection does not usually result in a notable clinical phenotype. Reports of
KSHV-associated mononucleosis or rash are few and far between. KSHV infection of
immune competent primates mirrors the paucity of phenotypes seen in human infection.
Recently, however, a new clinical entity has been proposed that describes a severe systemic
infection and/or reactivation with KSHV: KSHV-Inflammatory Cytokine Syndrome (KICS)
[21,25,26]. It is associated with high-level viremia, KS, and a severe cytokine storm in the
absence of MCD in HIV+ patients. Whether this rare disease is the result of a viral variant or
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a rare genetic predisposition, analogous to X-linked predispositions to chronic viral
infections, is presently unresolved. The most likely driver of the clinical phenotype seems to
be the production of KSHV vIL6 and human IL6 induction by KSHV.
KSHV in B cells
KSHV establishes latency in B cells. Latency in B cells can be asymptomatic and is mostly
likely restricted to a sub-set of B cells, which unlike EBV+ CD27+ memory B cells do not
circulate in large numbers in peripheral blood [27]. KSHV seems to have a predilection for
infecting and establishing long-term latency in only lambda expressing B cells [27,28].
KSHV infection drives primary B cells to proliferation[27]. Infection with the related
MHV68 virus also induced B cell hyperplasia and resulted in fully transformed B cells [29].
Individual KSHV latent genes induce B cell proliferative phenotypes in transgenic mice.
LANA transgenic mice developed splenic follicular hyperplasia, which is dependent on B
cell receptor (BCR) signaling [30]. vFLIP transgenic mice develop either lymphoma or
histiocydic sarcoma [31]. KSHV vIL6 transgenic mice develop hyperplasia reminiscent of
MCD [32]. The viral cyclin (vCyc) gene integrates different properties of the host cyclins to
foster a pro-growth and pro-virus environment [33]. Individual KSHV miRNAs also have
transforming properties in in vivo B cell models, particularly the KSHV mir-155 ortholog
[33,34]. Viral genes from the related MHV68 virus display similar phenotypes (reviewed in
[35]). B cell specific expression of multiple viral latent KSHV proteins as well as the viral
miRNAs leads to sustained hyperplasia, lymphoma, and hyper-responsiveness to antigen
stimulation [36].
A putative model of KSHV B cell pathogenesis would start with the primary infection event,
which drives the infected cell into an activated state. This holds true even for non-
permissively infected cells. In non-permissive cell sub-types, such as IgM+ kappa B cells, or
T cells [37], the virus is rapidly lost or the cell dies. In cells that are competent for the
establishment of latency, the virus persists and now confers a survival advantage to the
infected cell. The molecular nature of this advantage, and the exact complement of viral
genes that confer this advantage are not well defined. It may very well be that genes, other
than those consistently detected in KSHV tumor cells may contribute to this phenotype. This
model would be analogous perhaps to the establishment of EBV latency, which starts out
with expressing a more extensive set of genes (latency type II) and then contracts to latency
type I or even type 0.
MCD and PEL
Once established in B cells, KSHV can lead to multiple disease manifestations, as additional
mutations accumulate in the host genome over time. These B lymphoproliferative diseases
include primary effusion lymphoma (PEL) and the plasmablastic variant of multicentric
Castleman's disease (MCD) (reviewed in [38]) and in rare instances of diffuse large B cell
lymphoma not presenting as effusions. There is also the titillating observation that KSHV
increases the risk of marginal zone lymphoma (MZ) [39], and the ever present, but
controversial speculation that KSHV can be found in, contribute to, or survive better in
multiple myeloma cells.
MCD is considered a lymphoproliferative disorder rather than a frank lymphoma. The
KSHV infected plasmablasts invariably express IgM lambda. KSHV latent genes, as well as
the viral IL6 homolog are expressed in a large fraction of MCD cells (reviewed in [3,38]).
Unlike PEL, MCD cells do not express the CD138/syndecan-1 marker, and also do not show
hyper mutation of the IgG locus, which would argue that these cells did not participate in the
canonical germinal center reaction. The viral IL6 protein, as well as elevated human IL6,
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seems to drive much of the clinical symptomology of MCD, which provides a novel rational
target for intervention, perhaps using IL6 neutralizing antibodies [40].
PEL is a diffuse large B cell lymphoma of post germinal center origin [3,38]. All PEL cells
express CD138/syndecan-1, the KSHV LANA protein, the viral miRNAs and other latent
genes (vCYC, vFLIP, kaposin, vIRF3/LANA-2) [41,42]. A more detailed review about
KSHV gene expression is provided elsewhere in this issue. PEL cells contain many KSHV
episomes, ranging from 40 to 80 copies per cell. 50% of PEL are co-infected with EBV and
the EBV positive PEL exhibit a different pattern of gene expression compared to EBV-
negative PEL. At present there is no evidence that EBV-positive PEL have a different
clinical outcome, respond differently to treatment, or behave differently in experimental
models of tumor growth. In addition to KSHV, PEL have sustained multiple genomic
alterations as ascertained by CGH [43];Luan, 2010 #53}, though the total number of cases
has been too small to identify a single host cell driver mutation with a high degree of
statistical significance.
The relatively consistent growth of PEL cell lines in culture and the fact that many PEL can
be induced to release infectious KSHV have made them the workhorse for molecular studies
in KSHV pathogenesis. There is no evidence that the virus trapped in PEL cells is defective
(though the small number of cell lines which can be propagated in culture means that our
knowledge about PEL biology may be heavily biased). PEL represent the extreme end of
KSHV pathogenesis: a fully transformed cell, which maintains the KSHV genome in high
copy numbers, has acquired additional mutations, and which easily establishes tumors in
immune deficient mice (regardless of site of injection). Many PEL cell lines were derived
after, and thus selected to survive, multiple rounds of chemotherapy. Importantly, all PEL
cell lines depend on the presence of KSHV and the continued expression of KSHV genes for
survival (reviewed in [3,6,38]).
Modulation of the innate immune response by KSHV
Similar to other herpesviruses, KSHV has to escape the host immune response during initial
infection, during sustained latency, and during reactivation. The clinical experience is that
(i) KSHV successfully establishes latency and thus overcomes the initial host barriers to
infection, and (ii) that KS lesions spontaneously regress after immune reconstitution. MCD
also wanes with immune reconstitution and MCD symptoms have a cyclical pattern. PEL
never regresses but grows relentlessly in an immune compromised host. The survival time of
PEL in the absence of cytotoxic (and thus immune suppressive) therapy is less than the
typical time of immune reconstitution after cART initiation.
The host uses two levels of defense to counter microbial infection; the innate immune
system (initial recognition of the incoming pathogen) and the adaptive immune system
(systemic recognition and memory response to the pathogen). The innate immune response
initiates the adaptive response, which may eventually lead to pathogen clearance. KSHV has
evolved multiple molecular mechanisms to evade host immunity. These are described
elsewhere in this volume. Here we focus on one aspect to the virus-host interaction, which is
the interface of KSHV with the innate immune system.
Innate immunity is mediated by pattern recognition receptors (PRRs), which include the
Toll-like receptors (TLRs), RIG-I like receptors (RLRs) and nucleotide-binding
oligomerization domain, leucine rich repeat receptors (NLRs). TLRs, NLRs and RLRs differ
in localization, regulation, stimulus, and function. Most TLRs are found on the cell surface
and within endosomes, whereas the RLRs and NLRs are found within the cytosol. TLRs
recognize and bind to pathogen associated molecular patterns on the incoming pathogen. In
particular, TLR3, 7, 8 and 9 are all expressed in the endosome (reviewed in [44]). TLR3
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recognizes double stranded RNA, while TLR7/8 can recognize single stranded RNA. Both
ligands (ssRNA and dsRNA) are common intermediates in virus replication. TLR9
activation is induced upon exposure to CpG DNA in response to DNA viral infection [44].
TLR stimulation universally results in the upregulation of a large number of cytokines and
chemokines, most notably type 1 interferon (IFN).
RIG-I like receptors (RLRs) include RIG-I, MDA-5 and LGP2, which are cytosolic proteins
capable of sensing viral infection by binding double stranded and 5’-triphosphate RNAs.
RNA-bound RIG-I becomes activated and signals through mitochondrial antiviral signaling
protein (MAVS), a central node in intracellular PRR transduction pathways (reviewed in
[45]).
The nucleotide-binding oligomerization domain receptor (NLR) family of innate immune
sensors has been implicated in many human diseases (reviewed in [46]). NLRs sense
pathogen associated molecular patterns (PAMPs), danger associated molecular patterns
(DAMPs), as well as environmental irritants. Some NLR family members regulate innate
immunity through the formation of large molecular complexes called inflammasomes, which
lead to the upregulation of IL-1β and IL-18. However, other NLRs can inhibit NF-kB and
type I IFN signaling, suggesting that this pathway has evolved mechanisms to regulate itself.
Inflammasomes generally consist of oligomerization of a particular NLR, recruitment of
procaspase-1 and apoptotic-associated speck-like protein (ASC). To date, several NLR
family members have been shown to form inflammasomes including NLRP1, NLRP3, and
NLRC4. KSHV Orf63 was shown to inhibit NLRP1- and NLRP-3 inflammasome activity
and prevent the processing and activation of pro-IL-1β and pro-IL-18 to active IL-1β and
IL-18 [47]
There also exist non-NLR containing inflammasomes, and KSHV has been to shown to
activate interferon-inducible factor 16 (IFI16) to induce the inflammasome in KSHV-
infected endothelial cells [48,49].
Primary KSHV infection of human monocytes resulted in increased levels of TLR3 and
IFN-β production as well as several inflammatory cytokines [50]. In plasmacytoid dendritic
cells (pDCs), TLR9 has been reported to sense KSHV leading to increased IFN-α
production [51]. Furthermore, TLRs also play an important role during reactivation of
KSHV from latency [52] and TLR7/8 activation led to reactivation of KSHV from latency in
infected B cells. In endothelial cells, another cell type that harbors KSHV, KSHV infection
resulted in the downregulation of TLR4 [53].
KSHV encodes many immune evasion genes that block the IFN response. KSHV encodes
four different viral interferon regulatory factors (vIRFs) that display limited homology to
cellular IRFs. The vIRFs can block the function of cellular IRFs and inhibit their
transactivation of IFN-α and IFN-β (reviewed in [54]). Another KSHV viral protein, Orf45,
inhibits type I interferon expression by blocking IRF7 phosphorylation and its nuclear
accumulation, while ubiquitination and degradation of IRF7 and the TLR3 adaptor, TRIF, is
mediated by the KSHV Rta/Orf50 protein [55-57].
Conclusions
Our insights into KSHV have significantly advanced in the recent years. A new disease
entity (KICS) has been identified as being associated with acute KSHV replication.
Previously recognized KSHV diseases, such as KS, continue to lead the global cancer
burden in people living with HIV/AIDS. Additionally, recent advances have also been made
in our understanding of how KSHV modulates autophagy, host metabolism, differentiation
and innate immune responses. New tools, such as new animal model systems are on the
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horizon, which will allow us to investigate the life cycle of KSHV and of viral pathogenesis
prior to the development of disease phenotypes. At the same time, almost 20 years after the
discovery of KSHV, simple cytotoxic chemotherapy regimens remain the only clinically
validated treatments. Currently, there exists no vaccine against this virus and, with the
exception perhaps of mTOR inhibitors [17,58-60], no targeted agents have been added to
clinical practice.
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• We review recent advances in KSHV pathogenesis
• We review viral genes and microRNAs involved in KSHV pathogenesis
• We review clinical manifestations of KSHV-associated diseases
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Gross pathology of internal KS lesions on the lung of an AIDS patient (with permission
from Vincent J. Moylan).
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Different histological examples of KS. Shown is immunohistochemistry for the KSHV
LANA protein in brown (panels a to d) and Hematoxilin & Eosin (H&E) stain of lesions
(panel f. – i.) . Panels e and j represent non-KS control. The samples were part of the first
KS tissue microarray made available through the AIDS Cancer Specimen Resource (ACSR).
Magnification 40x.
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